Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Administration of AZD6738 · 1 trial · 3 indications
Safety measures include ECG, physical examination, pulse, blood pressure, body temperature, respiratory rate, weight and laboratory variables
| Arm | Type | Description |
|---|---|---|
| AZD6738 | EXPERIMENTAL | Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached. |
| Name | Type | Description |
|---|---|---|
| Administration of AZD6738 | DRUG | An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. 2. For the dose escalation phase, Part A, histological or cytological confirmation of relapsed or refractory B cell malignancy, including CLL, PLL, Burkitt l...
AZD6738 is an investigational small molecule being studied for the treatment of 11q-deleted relapsed/refractory chronic lymphocytic leukaemia (CLL), prolymphocytic leukaemia (PLL), and B cell lymphomas. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
AZD6738 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials for oncology indications.
AZD6738 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy.
AZD6738 has been studied in one completed Phase 1 clinical trial, identified as NCT01955668, titled "AZD6738 First Time in Patient Multiple Ascending Dose Study." This trial enrolled 2 participants with conditions including 11q-deleted relapsed/refractory chronic lymphocytic leukaemia, prolymphocytic leukaemia, and B cell lymphomas.
AZD6738 is also known as ceralasertib. It is an investigational small molecule being developed by AstraZeneca for the treatment of certain haematological malignancies, including 11q-deleted relapsed/refractory chronic lymphocytic leukaemia.